MorphoSys AG

NasdaqGS:MOR Stock Report

Market Cap: US$2.8b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Future Growth

Future criteria checks 2/6

MorphoSys is forecast to grow earnings and revenue by 59.1% and 25% per annum respectively. EPS is expected to grow by 78.2% per annum. Return on equity is forecast to be 7.7% in 3 years.

Key information

59.1%

Earnings growth rate

78.2%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate25.0%
Future return on equity7.7%
Analyst coverage

Good

Last updated05 Aug 2024

Recent future growth updates

Recent updates

MorphoSys: Hold Rating Until The Novartis Deal Closes

May 01

Novartis And MorphoSys Are A Perfect Match

Feb 06

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

Jan 18

MorphoSys updates Q2 & FY22 guidance below prior provided levels

Jul 26

MorphoSys May Not Recover From Adventurous Constellation Buyout

May 04

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Jan 28

Incyte and MorphoSys presents new three-year data for blood cancer therapy

Jun 04

MorphoSys reports Q1 results

May 05

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Jan 06

MorphoSys AG (MOR) Investor Presentation - Slideshow

Dec 08

MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation

Nov 22

MorphoSys reports Q3 results

Nov 11

Earnings and Revenue Growth Forecasts

NasdaqGS:MOR - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026425-78-120-505
12/31/2025322-140-236-2018
12/31/2024180-249-296-2533
3/31/2024241-469-286-284N/A
12/31/2023238-190-299-296N/A
9/30/2023223104-363-355N/A
6/30/2023255100-349-338N/A
3/31/2023261-61-321-306N/A
12/31/2022278-151-382-367N/A
9/30/2022250-861-436-417N/A
6/30/2022195-851-606-588N/A
3/31/2022174-596-610-583N/A
12/31/2021180-514-508-481N/A
9/30/2021163-150-423-393N/A
6/30/2021143-103-295-246N/A
3/31/2021124-177-255-217N/A
12/31/202032898-1435N/A
9/30/2020303642663N/A
6/30/202029310598113N/A
3/31/2020309153137152N/A
12/31/201972-103-85-81N/A
9/30/201971-96-68-64N/A
6/30/2019114-42-42-39N/A
3/31/201987-59-33-31N/A
12/31/201876-56-35-33N/A
9/30/201894-27-16-14N/A
6/30/201854-82-61-48N/A
3/31/201858-74-68-55N/A
12/31/201767-70N/A-38N/A
9/30/201752-84N/A-52N/A
6/30/201749-73N/A-59N/A
3/31/201749-68N/A-47N/A
12/31/201650-60N/A-47N/A
9/30/201649-45N/A-48N/A
6/30/201648-40N/A-41N/A
3/31/201648-33N/A-35N/A
12/31/201510615N/A-24N/A
9/30/201511127N/A-15N/A
6/30/201511633N/A-3N/A
3/31/201511937N/A-4N/A
12/31/201464-3N/A-14N/A
9/30/201461-6N/A-15N/A
6/30/201460-5N/A79N/A
3/31/2014777N/A76N/A
12/31/2013787N/A89N/A
9/30/20138014N/A100N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOR's revenue (25% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: MOR's revenue (25% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MOR's Return on Equity is forecast to be low in 3 years time (7.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y